Efficacy of Morin as a Potential Therapeutic Phytocomponent: Insights into the Mechanism of Action

[1] Jin, H. et al. “Morin, a flavonoid from moraceae, suppresses growth and invasion of the highly metastatic
breast cancer cell line MDA-MB-231 partly through suppression of the Akt pathway.” International Journal of
Oncology Vol. 45, No. 4, 2014, pp. 1629-37.
[2] Lemkul, J.A., and D.R. Bevan. “Destabilizing Alzheimer’s Aβ42 protofibrils with morin: Mechanistic insights
from molecular dynamics simulations.” Biochemistry Vol. 49, No. 18, 2010, pp. 3935-46.
[3] Noor, H. et al. “Morin hydrate inhibits amyloid formation by islet amyloid polypeptide and disaggregates amyloid
fibers.” Protein Science Vol. 21, No. 3, 2012, pp. 373-82.
[4] Caselli, A. et al. “Morin: A promising natural drug.” Current Medicinal Chemistry Vol. 23, No. 8, 2016, pp.
774-91.
[5] Caruana, M., Högen T. et al. “Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic
compounds.” FEBS Letters Vol. 585, No. 8, 2011, pp. 1113-20.
[6] Gottlieb, M. et al. “Neuroprotection by two polyphenols following excitotoxicity and experimental ischemia.”
Neurobiology of Disease Vol. 23, No. 2, 2006, pp. 374-86.
[7] Al-Numair, K.S., et al. “Morin, a flavonoid, on lipid peroxidation and antioxidant status in experimental myocardial
ischemic rats.” African Journal of Traditional, Complementary, and Alternative Medicines: AJTCAM/African
Networks on Ethnomedicines Vol. 11, No. 3, 2014, pp. 14-20.
[8] Ola, M.S. et al. “Flavonoid, morin inhibits oxidative stress, inflammation and enhances neurotrophic support in
the brain of streptozotocin-induced diabetic rats.” Neurological Sciences Vol. 35, No. 7, 2014, pp. 1003-08.
[9] Paoli, P. et al. “The insulin-mimetic effect of morin: A promising molecule in diabetes treatment.” Biochimica et
Biophysica Acta - General Subjects Vol. 1830, No. 4, 2013, pp. 3102-11.
[10] Kapoor, R, and Kakkar P. “Protective role of morin, a flavonoid, against high glucose induced oxidative stress
mediated apoptosis in primary rat hepatocytes.” PLoS ONE, Vol. 7, No. 8, 2012.
[11] Birt, D. F., et al. “Dietary agents in cancer prevention: Flavonoids and isoflavonoids.” Pharmacology and
Therapeutics, Vol. 90, No. 2-3, 2001, pp. 157-77.
[12] Zhang, S, and Morris, M.E. “Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on
P-glycoprotein-mediated transport.” The Journal of Pharmacology and Experimental Therapeutics, Vol. 304,
No. 3, 2003, pp. 1258-67.
[13] Zhang, S., Yang, X., and Morris. M.E. “Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-
mediated transport.” Molecular Pharmacology, Vol. 65, No. 5, 2004, pp. 1208-16.
[14] García-Lafuente, A. et al. “Flavonoids as anti-inflammatory agents: Implications in cancer and cardiovascular
disease.” Inflammation Research, Vol. 58, No. 9, 2009, pp. 537-52.
[15] Wu, T.W., Ling H.Z., et al. “Morin: A wood pigment that protects three types of human cells in the cardiovascular
system against oxyradical damage.” Biochemical Pharmacology, Vol. 47, No. 6, 1994, pp. 1099-103.
[16] Prahalathan, P., et al. “Effect of morin, a flavonoid against DOCA-salt hypertensive rats: A dose dependent
study.” Asian Pacific Journal of Tropical Biomedicine, Vol. 2, No. 6, 2012, pp. 443-48.
[17] Chen Y. et al. “Flavonoids as superoxide scavengers and antioxidants.” Free Radical Biology and Medicine, Vol.
9, No. 1, 1990, pp. 19-21.
[18] Choi, J. S., and Han, H. K. “Pharmacokinetic interaction between diltiazem and morin, a flavonoid, in rats.”
Pharmacological Research, Vol. 52, No. 5, 2005, pp. 386-91.
[19] Milbury, P.E. et al. “Determination of flavonoids and phenolics and their distribution in almonds.” Journal of
Agricultural and Food Chemistry, Vol. 54, No. 14, 2006, pp. 5027-33.
[20] Xie, M-X, et al. “Characterization of the interaction between human serum albumin and morin.” Biochimica et
Biophysica Acta Vol. 1760, No. 8, 2006, pp. 1184-91.
[21] Fang, S.H., et al. “Morin sulfates/glucuronides exert anti-inflammatory activity on activated macrophages and
decreased the incidence of septic shock.” Life Sciences, Vol. 74, No. 6, 2003, pp. 743-56.
Choudhury, et al. Int J Med Res Health Sci 2017, 6(11): 175-194
185
[22] Gálvez, J., et al. “Intestinal anti-inflammatory activity of morin on chronic experimental colitis in the rat.”
Alimentary Pharmacology and Therapeutics, Vol. 15, No. 12, 2001, pp. 2027-39.
[23] Du, Y, et al. “Morin reverses neuropathological and cognitive impairments in APPswe/PS1dE9 mice by targeting
multiple pathogenic mechanisms.” Neuropharmacology Vol. 108, 2016, pp. 1-13.
[24] Panhwar, Q.K., et al. “Synthesis, characterization, spectroscopic and antioxidation studies of Cu(II)-morin
complex.” Journal of Molecular Structure Vol. 967, No. 1-3, 2010, pp. 47-53.
[25] Bartalena, L., and Robbins, J. “Variations in thyroid hormone transport proteins and their clinical implications.”
Thyroid : Official Journal of the American Thyroid Association Vol. 2, No. 3, 1992, pp. 237-45.
[26] Cook, N.C., and Samman, S. “Flavonoids-chemistry, metabolism, cardioprotective effects, and dietary sources’.
The Journal of Nutritional Biochemistry Vol. 7, no. 2, 1996, pp. 66-76.
[27] Chen, C. Olive, Y. Blumberg, J.B. “Phytochemical composition of nuts.” Asia Pacific Journal of Clinical
Nutrition Vol. 17, No. SUPPL. 1, 2008, pp. 329-32.
[28] Jiminez-Escrig, A., et al. “Guava fruit (Psidium guajava L.) as a new source of antioxidant dietary fiber.”
Journal of Agricultural and Food Chemistry Vol. 49, No. 11, 2001, pp. 5489-93.
[29] Lamounier, K. C., et al. “Chemical analysis and study of phenolics, antioxidant activity, and antibacterial effect of
the wood and bark of Maclura tinctoria (L.) D. Don Ex Steud.” Evidence-Based Complementary and Alternative
Medicine : eCAM Vol. 2012, 2012, p. 451039.
[30] Tsao, R. et al. “Antioxidant isoflavones in osage orange, Maclura pomifera (Raf.) Schneid.” Journal of
Agricultural and Food Chemistry Vol. 51, No. 22, 2003, pp. 6445-51.
[31] Hussain, J. et al. “Isolation and bioactivities of the flavonoids morin and morin-3-o-β-d-glucopyranoside from
Acridocarpus orientalis - A wild Arabian medicinal plant.” Molecules Vol. 19, No. 11, 2014, pp. 17763-72.
[32] Kim, Ji-S. et al. “Comparison of phenolic acids and flavonoids in black garlic at different thermal processing
steps.” Journal of Functional Foods, Vol. 5, No. 1, 2013, pp. 80-86.
[33] Osman, A., and Makris D. P. “Oxidation of morin (2’,3,4’,5,7-Pentahydroxyflavone) with a peroxidase
homogenate from onion.” International Food Research Journal Vol. 18, No. 3, 2011, pp. 1039-43.
[34] Aoyama, S., and Yamamoto, Y. “Antioxidant activity and flavonoid content of welsh onion (Allium fistulosum)
and the effect of thermal treatment.” Food Science and Technology Research, Vol. 13, No. 1, 2007, pp. 67-72.
[35] Geetha, M., et al. “Extraction of anthocyanin and analyzing its antioxidant properties from different onion
(Allium cepa) varieties.” ©JK Welfare & Pharmascope Foundation | International Journal of Research in
Pharmaceutical Sciences, Vol. 2, No. 3, 2011, pp. 497-506.
[36] Trichopoulou, A., et al. “Nutritional composition and flavonoid content of edible wild greens and green pies: A
potential rich source of antioxidant nutrients in the mediterranean diet.” Food Chemistry, Vol. 70, No. 3, 2000,
pp. 319-23.
[37] Si, W., et al. “Bioassay-guided purification and identification of antimicrobial components in Chinese green tea
extract.” Journal of Chromatography A Vol. 1125, No. 2, 2006, pp. 204-10.
[38] Whitehead, T.P., et al. “Effect of red wine ingestion on the antioxidant capacity of serum.” Clinical Chemistry
Vol. 41, No. 1, 1995, pp. 32-35.
[39] Somoza, V., et al. “Activity-guided identification of a chemopreventive compound in coffee beverage using in
vitro and in vivo techniques.” Journal of Agricultural and Food Chemistry Vol. 51, No. 23, 2003, pp. 6861-69.
[40] Lee, Ki-W. et al. “Cocoa has more phenolic phytochemicals and a higher antioxidant capacity than teas and red
wine.” Journal of Agricultural and Food Chemistry Vol. 51, No. 25, 2003, pp. 7292-95.
[41] Decker, E. et al. “Whole Grains as a Source of Antioxidants.” Cereal Foods World Vol. 47, No. 8, 2002, pp.
370-73.
[42] Subash, S., and Subramanian, P. “Morin a flavonoid exerts antioxidant potential in chronic hyperammonemic
rats: A biochemical and histopathological study.” Molecular and Cellular Biochemistry Vol. 327, No. 1-2, 2009,
pp. 153-61.
Choudhury, et al. Int J Med Res Health Sci 2017, 6(11): 175-194
186
[43] Subash, S., and Subramanian, P. “Effect of morin on the levels of circulatory liver markers and redox status in
experimental chronic hyperammonaemic rats.” Singapore Medical Journal Vol. 49, No. 8, 2008, pp. 650-55.
[44] Dhanasekar, C. et al. “Morin, a bioflavonoid suppresses monosodium urate crystal-induced inflammatory
immune response in RAW 264.7 macrophages through the inhibition of inflammatory mediators, intracellular
ROS levels and NF-κB activation.” PLoS ONE Vol. 10, No. 12, 2015.
[45] Ratty, A.K., and Das N.P. “Effects of flavonoids on nonenzymatic lipid peroxidation: Structure-activity
relationship.” Biochemical Medicine and Metabolic Biology Vol. 39, No. 1, 1988, pp. 69-79.
[46] Walle, T. “Absorption and Metabolism of Flavonoids’. Free Radical Biology and Medicine Vol. 36, No. 7, 2004,
pp. 829-37.
[47] Oteiza, P.I., et al. “Flavonoid-membrane interactions: A protective role of flavonoids at the membrane surface?’
Clinical and Developmental Immunology Vol. 12, No. 1, 2005, pp. 19-25.
[48] Hendrich, A.B. “Flavonoid-membrane interactions: Possible consequences for biological effects of some
polyphenolic compounds.” Acta Pharmacologica Sinica Vol. 27, No. 1, 2006, pp. 27-40.
[49] Wesołowska, O. “Interaction of phenothiazines, stilbenes and flavonoids with multidrug resistance-associated
transporters, p-glycoprotein and MRP1’. Acta Biochimica Polonica Vol. 58, No. 4, 2011, pp. 433-48.
[50] Gordon, D.J., et al. “High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American
studies.” Circulation, Vol. 79, No. 1, 1989, pp. 8-15.
[51] Moffett, S.P., et al. “Tumor necrosis factor-alpha polymorphism, bone strength phenotypes, and the risk of
fracture in older women.” The Journal of Clinical Endocrinology and Metabolism Vol. 90, No. 6, 2005, pp.
3491-97.
[52] Nakazawa, T, et al. “Tumor necrosis factor-alpha mediates photoreceptor death in a rodent model of retinal
detachment.” Investigative Ophthalmology & Visual Science Vol. 52, No. 3, 2011, pp. 1384-91.
[53] Hougee, S. et al. “Decreased pro-inflammatory cytokine production by LPS-stimulated PBMC upon in
vitro incubation with the flavonoids apigenin, luteolin or chrysin, due to selective elimination of monocytes/
macrophages.” Biochemical Pharmacology Vol. 69, No. 2, 2005, pp. 241-48.
[54] Wang, X. et al. “Morin reduces hepatic inflammation-associated lipid accumulation in high fructose-fed rats via
inhibiting sphingosine kinase 1/sphingosine 1-phosphate signaling pathway.” Biochemical Pharmacology Vol.
86, No. 12, 2013, pp. 1791-804.
[55] Prahalathan, P., Saravanakumar, M. et al. “The flavonoid morin restores blood pressure and lipid metabolism in
DOCA-salt hypertensive rats’. Redox Report, vol. 17, no. 4, 2012, pp. 167-75.
[56] Hardy, J. “The amyloid hypothesis of Alzheimer’s Disease: Progress and problems on the road to therapeutics.”
Science Vol. 297, No. 5580, 2002, pp. 353-56.
[57] Goedert, M., and Spillantini, M. G. “A century of Alzheimer’s disease.” Science Vol. 314, No. 5800, 2006, pp.
777-81.
[58] Geetha, C., Pugazhenthi D. “Classification of Alzheimer’s disease subjects from MRI using fuzzy neural network
with feature extraction using discrete wavelet transform.” Biomedical Research Vol. 1, No. 1, 2017, p. 234.
[59] Smith, D.G. et al. “The redox chemistry of the alzheimer’s disease amyloid β peptide.” Biochimica et Biophysica
Acta - Biomembranes Vol. 1768, No. 8, 2007, pp. 1976-90.
[60] Mattson, M.P. “Pathway towards and away from Alzheimer’s disease.” Nature, Vol. 430, No. 7000, 2004, pp.
631-39.
[61] Kopcho, L.M., et al. “Comparative studies of active site-ligand interactions among various recombinant
constructs of human β-amyloid precursor protein cleaving enzyme.” Archives of Biochemistry and Biophysics
Vol. 410, No. 2, 2003, pp. 307-16.
[62] Gong, E.- Ji, et al. “Morin attenuates tau hyperphosphorylation by inhibiting GSK3β.” Neurobiology of Disease
Vol. 44, No. 2, 2011, pp. 223-30.
[63] Planel, E. et al. “Role of GSK-3β in Alzheimer’s disease pathology.” Drug Development Research Vol. 56, No.
3, 2002, pp. 491-510.
Choudhury, et al. Int J Med Res Health Sci 2017, 6(11): 175-194
187
[64] Hurtado, D.E., et al. “Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of
Alzheimer’s disease.” Journal of Neuroscience Vol. 32, No. 21, 2012, pp. 7392-402.
[65] Glen, A. I., et al. “Choline uptake in patients with alzheimer pre-senile dementia’. Psychological Medicine Vol.
11, No. 0033-2917, 1981, pp. 469-76.
[66] Amor, S. et al. “Inflammation in neurodegenerative diseases.” Immunology Vol. 129, No. 2, 2010, pp. 154-69.
[67] Petit-Paitel, A. “GSK-3beta: A central kinase for neurodegenerative diseases?” Med Sci (Paris), Vol. 26, No. 5,
2010, pp. 516-21.
[68] Pei, J-J. et al. “Distribution of active glycogen synthase kinase 3β (GSK-3β) in brains staged for Alzheimer
disease neurofibrillary changes.” Journal of Neuropathology and Experimental Neurology Vol. 58, No. 9, 1999,
pp. 1010-19.
[69] Jo, J. et al. “Aβ1-42 Inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-
3β.” Nature Neuroscience Vol. 14, No. 5, 2011, pp. 545-47.
[70] Llorens-Martín, M., et al. “GSK-3β overexpression causes reversible alterations on postsynaptic densities and
dendritic morphology of hippocampal granule neurons in vivo.” Molecular Psychiatry Vol. 18, No. 4, 2013, pp.
451-60.
[71] MadanKumar, P., et al. “Morin ameliorates chemically induced liver fibrosis in vivo and inhibits stellate cell
proliferation in vitro by suppressing Wnt/beta-catenin signaling.” Toxicology and Applied Pharmacology Vol.
277, No. 2, 2014, pp. 210-20.
[72] Kim, Ji, M. et al. “Morin modulates the oxidative stress-induced NF-kappaB pathway through its anti-oxidant
activity.” Free Radical Research Vol. 44, No. 4, 2010, pp. 454-61.
[73] Lawrence, T. “The nuclear factor NF-kappaB pathway in inflammation.” Cold Spring Harbor Perspectives in
Biology Vol. 1, No. 6, 2009.
[74] Giuliani, C., et al. “Nf-kB Transcription factor: Role in the pathogenesis of inflammatory, autoimmune, and
neoplastic diseases and therapy implications.” Clinical Therapeutics Vol. 152, No. 4, 2001, pp. 249-53.
[75] Remya, C., et al. “Design of potent inhibitors of acetylcholinesterase using morin as the starting compound.”
Frontiers in Life Science Vol. 6, No. 3-4, 2012, pp. 107-17.
[76] Liu, F-F. et al. “Molecular insight into conformational transition of amyloid β-peptide 42 inhibited by
(−)-epigallocatechin-3-gallate probed by molecular simulations.’ The Journal of Physical Chemistry Vol. 115,
No. 41, 2011, pp. 11879-87.
[77] Lu, C-J., and Larry E. Tune. “Chronic exposure to anticholinergic medications adversely affects the course of
Alzheimer disease.” The American Journal of Geriatric Psychiatry Vol. 11, No. 4, 2003, pp. 458-61.
[78] Shimmyo, Y. et al. “Flavonols and flavones as BACE-1 Inhibitors: Structure-activity relationship in cell-free,
cell-based and in silico studies reveal novel pharmacophore features.” Biochimica et Biophysica Acta - General
Subjects Vol. 1780, No. 5, 2008, pp. 819-25.
[79] Anand, P., and Singh, B. “Flavonoids as lead compounds modulating the enzyme targets in alzheimer’s disease.”
Medicinal Chemistry Research Vol. 22, No. 7, 2013, pp. 3061-75.
[80] Ma SH, Zhang LL, Jiang QQ. “Protective Effect of Bioflavonoid Morin on Cadmium Induced Oxidative
Neuropathy.” Biomedical Research Vol. 28, No. 3, 2017, pp. 1148-54.
[81] Kalia, L.V., and Lang, A.E. ‘Parkinson’s disease.” The Lancet, vol. 386, no. 9996, 2015, pp. 896–912.
[82] Dauer, W., and Przedborski, S. “Parkinson’s Disease: Mechanisms and models.” Neuron Vol. 39, No. 6, 2003,
pp. 889-909.
[83] Zhang, Z-T., Xue-bing, C., Xiong, N. et al. “Morin exerts neuroprotective actions in parkinson disease models
in vitro and in vivo.” Acta Pharmacologica Sinica, Vol. 31, No. 8, 2010, pp. 900-06.
[84] Solanki, I., et al. “Flavonoid-based therapies in the early management of neurodegenerative diseases.” Advances
in Nutrition: An International Review Journal Vol. 6, No. 1, 2015, pp. 64-72.
[85] Selvakumar, G.P, Manivasagam A.A. “Neurotoxicity associated with neuroleptic haloperidol induced tardive
Choudhury, et al. Int J Med Res Health Sci 2017, 6(11): 175-194
188
dyskinesia in Albino mice: Protective role of morin.” Journal of Pharmacy Research, Vol. 5, No. 7, 2012, pp.
3633-39.
[86] Chang, P. K.Y., et al. “AMPA Receptors as drug targets in neurological disease - Advantages, caveats, and future
outlook.” European Journal of Neuroscience Vol. 35, No. 12, 2012, pp. 1908-16.
[87] Liu, H.N. et al. “AMPA Receptor-mediated toxicity in oligodendrocyte progenitors involves free radical
generation and activation of JNK, calpain and caspase 3.” Journal of Neurochemistry Vol. 82, No. 2, 2002, pp.
398-409.
[88] Ibarretxe, G. et al. “Differential oxidative stress in oligodendrocytes and neurons after excitotoxic insults and
protection by natural polyphenols.” GLIA, Vol. 53, No. 2, 2006, pp. 201-11.
[89] Lee, C.H. et al. “Bioactive compounds from natural product extracts in Taiwan cosmeceuticals-Mini review.”
Biomedical Research (India) Vol. 28, No. 15, 2017, pp. 6561-66.
[90] Caruana, M., Neuner, J. et al. “Polyphenolic compounds are novel protective agents against lipid membrane
damage by α-synuclein aggregates in vitro.” Biochimica et Biophysica Acta - Biomembranes Vol. 1818, No. 11,
2012, pp. 2502-10.
[91] Cho, Y. M., et al. “A 13-week subchronic toxicity study of dietary administered morin in F344 rats.” Food and
Chemical Toxicology Vol. 44, No. 6, 2006, pp. 891-97.
[92] Arriagada, F., et al. “Morin flavonoid adsorbed on mesoporous silica, a novel antioxidant nanomaterial.” PLoS
ONE Vol. 11, No. 11, 2016.
[93] Velasco, M. “Toxicity of maneb and mancozeb pesticides contributing to rat pheochromocytoma cellular
death and the potential neuroprotective effects of polyphenols against these insults.” International Journal of
Toxicology Vol. 31, No. 1, 2012, pp. 117-18.
[94] Iglesias, C.V. et al. “Effects of morin on snake venom phospholipase A2 (PLA 2).” Toxicon Vol. 46, No. 7, 2005,
pp. 751-58.
[95] Park, C., et al. “Morin, a flavonoid from moraceae, induces apoptosis by induction of bad protein in human
leukemic cells.” International Journal of Molecular Sciences Vol. 16, No. 1, 2015, pp. 645-59.
[96] Chaurasiya, N.D., et al. “Monoamine oxidase inhibitory constituents of propolis: Kinetics and mechanism of
inhibition of recombinant human MAO-A and MAO-B.” Molecules, Vol. 19, No. 11, 2014, pp. 18936-52.
[97] Kapinya, K.J., et al. “Isoflurane induced prolonged protection against cerebral ischemia in mice: a redox sensitive
mechanism?” Neuroreport Vol. 13, No. 11, 2002, pp. 1431-35.
[98] Yager, J.Y., et al. “Cerebral oxidative metabolism and redox state during hypoxia-ischemia and early recovery
in immature rats.” American Journal of Physiology Vol. 261, No. 4 Pt 2, 1991, pp. H1102-8.
[99] Prince PG, Hemamalini RR, Kumar S. “Seizure detection by classification of EEG signals based on dwt
reconstruction error and CWT using a novel wavelet.” Biomedical Research Vol. 26, No. 3, 2015, pp. 530-33.
[100] Nikcevic L, Savic M, Lazovic M, Hrkovic M, Mujovic N, Nikolic D. “The influence of early thrombolysis on
c-reactive protein values and functional outcome after acute ischemic stroke.” Biomedical Research Vol. 27,
No. 4, 2016, pp. 1183-87.
[101] Iqbal J, Baizid K. “Stroke rehabilitation using exoskeleton-based robotic exercisers: Mini review.” Biomedical
Research Vol. 26, No. 1, 2015, pp. 197-201.
[102] Schmitt-Schillig, S., et al. “Flavonoids and the aging brain.” Journal of Physiology and Pharmacology Vol. 56,
No. SUPPL. 1, 2005, pp. 23-36.
[103] Rishika, Dev and Sharma, R. “An update of pharmacological activity of Psidium guajava in the management of
various disorders.” Pharmaceutical Vol. 3, No. 10, 2012, pp. 3577-84.
[104] Sanda, K.A., et al. “Pharmacological aspects of Psidium guajava: An update.” International Journal of
Pharmacology Vol. 7, No. 3, 2011, pp. 316-24.
[105] Joseph, B, and Priya R.M. “Review on nutritional, medicinal and pharmacological properties of guava (Psidium
guajava Linn.).” International Journal of Pharma and Bio Sciences Vol. 2, No. 1, 2011, pp. 53-69.
[106] Zhang, R., Kyoung A.K., Sam S.K. et al. “Morin (2 ’,3,4 ’,5,7-Pentahydroxyflavone) protected cells against
Choudhury, et al. Int J Med Res Health Sci 2017, 6(11): 175-194
189
gamma-radiation-induced oxidative stress.” Basic & Clinical Pharmacology & Toxicology Vol. 108, No. 1,
2011, pp. 63-72.
[107] Kim, H.P. et al. “Anti-Inflammatory plant flavonoids and cellular action mechanisms.” Journal of
Pharmacological Sciences Vol. 96, No. 3, 2004, pp. 229-45.
[108] Sivaramakrishnan, V., and Sivasitambaram N.D. “Morin fosters apoptosis in experimental hepatocellular
carcinogenesis model.” Chemico-Biological Interactions Vol. 183, No. 2, 2010, pp. 284-92.
[109] Sivaramakrishnan, V., and Devaraj, S.N. “Morin regulates the expression of NF-kB-p65, COX-2 and
matrix metalloproteinases in diethylnitrosamine induced rat hepatocellular carcinoma.” Chemico-Biological
Interactions Vol. 180, No. 3, 2009, pp. 353-59.
[110] Madankumar, P., et al. “Morin, a dietary flavonoid, exhibits anti-fibrotic effect and induces apoptosis of activated
hepatic stellate cells by suppressing canonical NF-kB signaling.” Biochimie Vol. 110, 2015, pp. 107-18.
[111] Sase T, Arito M, Onodera H, Kurokawa MS, Tanaka Y, Kato T. “Effects of edaravone on hypoxic human
astrocytes revealed by a proteomic approach.” Biomedical Research Vol. 27, No. 4, 2016, pp. 1064-70.
[112] Lee CH, Huang GC and Chen CY. “Bioactive compounds from natural product extracts in taiwan cosmeceuticalsmini
review.” Biomedical Research Vol. 28, No. 15, 2017, pp. 6561-66.
[113] Van-Der-Sluis, A.A., et al. “Flavonoids as Bioactive Components in Apple Products.” Cancer Letters Vol. 114,
No. 1-2, 1997, pp. 107-08.
[114] Yenjai, C. et al. “Bioactive flavonoids from Kaempferia parviflora’. Fitoterapia, vol. 75, no. 1, 2004, pp. 89-92.
[115] Comalada, M. et al. “Flavonoids and immunomodulation.” Bioactive Food as Interventions for Arthritis and
Related Inflammatory Diseases, 2013, pp. 555–79.
[116] Chokchaisiri, R. et al. “Bioactive flavonoids of the flowers of butea monosperma.’ Chemical & Pharmaceutical
Bulletin, Vol. 57, No. 4, 2009, pp. 428-32.
[117] Macías, F.A., et al. “Bioactive flavonoids from helianthus annuus cultivars.” Phytochemistry Vol. 45, No. 4,
1997, pp. 683-87.
[118] Cushnie, T.P., and Lamb. A.J. “Recent advances in understanding the antibacterial properties of flavonoids.”
International Journal of Antimicrobial Agents Vol. 38, No. 2, 2011, pp. 99-107.
[119] Harborne, J.B., and Williams, C.A. “Advances in flavonoid research since 1992.” Phytochemistry Vol. 55, No.
6, 2000, pp. 481-504.
[120] Cushnie, T.P.T., and Lamb, A.J. “Recent advances in understanding the antibacterial properties of flavonoids.”
International Journal of Antimicrobial Agents Vol. 38, No. 2, 2011, pp. 99-107.
[121] Kang, S.S., et al. “Flavonols inhibit sortases and sortase-mediated staphylococcus aureus clumping to
fibrinogen.” Biological & Pharmaceutical Bulletin Vol. 29, No. 8, 2006, pp. 1751-55.
[122] Ton-That, H., et al. “Anchoring of surface proteins to the cell wall of staphylococcus aureus. sortase catalyzed
in vitro transpeptidation reaction using LPXTG peptide and NH2-GLY3 substrates.” Journal of Biological
Chemistry Vol. 275, No. 13, 2000, pp. 9876-81.
[123] Ton-That, H., et al. “Purification and characterization of sortase, the transpeptidase that cleaves surface proteins
of Staphylococcus aureus at the LPXTG motif.” Proceedings of the National Academy of Sciences Vol. 96, No.
22, 1999, pp. 12424-29.
[124] Mazmanian, S. k. “Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the Cell Wall.”
Science Vol. 285, No. 5428, 1999, pp. 760-63.
[125] Xu, H., et al. “Flavones inhibit the hexameric replicative helicase RepA.” Nucleic Acids Research Vol. 29, No.
24, 2001, pp. 5058-66.
[126] Arima, Hidetoshi, and Gen-ichi Danno. “Isolation of antimicrobial compounds from guava (Psidium guajava
l.) and their structural elucidation.” Bioscience, Biotechnology, and Biochemistry Vol. 66, No. 8, 2002, pp.
1727-30.
[127] Rattanachaikunsopon P, Phumkhachorn P. “Contents and antibacterial activity of flavonoids extracted from
leaves of Psidium guajava.” Journal of Medicinal Plants Research Vol. 4, No. 5, 2010, p. 393-96.
Choudhury, et al. Int J Med Res Health Sci 2017, 6(11): 175-194
190
[128] Abdulazeez SS. “Freeze dried strawberry powder ameliorates alloxan induced hyperlipidemia in diabetic rats.”
Biomedical Research Vol. 26, No. 1, 2015, pp. 77-81.
[129] Zhang W, Liu S. “Study on the determination of lactone contents in ginkgo biloba leaves and their effects in
schizophrenia.” Biomedical Research Vol. 26, No. 1, 2015, pp. 31-36.
[130] Hassanalilou, Tohid, et al. “The protective effects of morus nigra l. leaves on the kidney function tests and
kidney and liver histological structures in streptozotocin-induced diabetic rats.” Biomedical Research Vol. 28,
no. 14, 2017, pp. 6113-18.
[131] Basha, S.K., and Vinoji S.K., “In vitro antidiabetic activity of Psidium guajava leaves extracts.” Asian Pacific
Journal of Tropical Disease Vol. 2, No. SUPPL.1, 2012.
[132] Mazumdar, S., et al. “Anti-diabetic and antidiarrhoeal effects on ethanolic extract of Psidium guajava (L.) Bat.
Leaves in Wister Rats.” Asian Pacific Journal of Tropical Biomedicine, Vol. 5, No. 1, 2015, pp. 10-14.
[133] Oh, W.K., et al. “Anti-diabetic effects of extracts from Psidium guajava.” Journal of Ethnopharmacology Vol.
96, No. 3, 2005, pp. 411-15.
[134] Vanitha, P., et al. “Modulatory effects of morin on hyperglycemia by attenuating the hepatic key enzymes of
carbohydrate metabolism and cell function in streptozotocin-induced diabetic rats.” Environmental Toxicology
and Pharmacology Vol. 37, No. 1, 2014, pp. 326-35.
[135] Huang, C.S., et al. “Anti-hyperglycemic and antioxidative potential of Psidium guajava fruit in streptozotocininduced
diabetic rats.” Food and Chemical Toxicology Vol. 49, No. 9, 2011, pp. 2189-95.
[136] Subramanian, S., et al. “Biochemical evaluation of antihyperglycemic and antioxidant nature of Psidium
guajava leaves extract in streptozotocin-induced experimental diabetes in rats.” Pharmaceutical Biology Vol.
47, No. 4, 2009, pp. 298-303.
[137] Vinayagam, R., and Xu, B. “Anti-diabetic properties of dietary flavonoids: A cellular mechanism review.”
Nutrition & Metabolism Vol. 12, No. 1, 2015, p. 60.
[138] Badea, M., et al. “Thermal behavior of some vanadyl complexes with flavone derivatives as potential insulinmimetic
agents.” Journal of Thermal Analysis and Calorimetry Vol. 105, No. 2, 2011, pp. 559-64.
[139] Alsharari, S.D., et al. “Ameliorative potential of morin in streptozotocin-induced neuropathic pain in rats.”
Tropical Journal of Pharmaceutical Research Vol. 13, No. 9, 2014, pp. 1429-36.
[140] Lin, M.H., et al. “Investigation of morin-induced insulin secretion in cultured pancreatic cells.” Clinical and
Experimental Pharmacology and Physiology 2017.
[141] Nafisi, S., et al. “DNA adducts with antioxidant flavonoids: Morin, apigenin, and naringin.” DNA and Cell
Biology Vol. 27, No. 8, 2008, pp. 433-42.
[142] Nafisi, Sh, et al. “RNA binding to antioxidant flavonoids.” Journal of Photochemistry and Photobiology B:
Biology Vol. 94, No. 1, 2009, pp. 1-7.
[143] Payán-Gómez, S.A., et al. “Computational molecular characterization of the flavonoid morin and its Pt(II),
Pd(II) and Zn(II) complexes.” Journal of Molecular Modeling Vol. 17, No. 5, 2011, pp. 979-85.
[144] Selvaraj, S., et al. ‘Flavonoid-metal ion complexes: A novel class of therapeutic agents.” Medicinal Research
Reviews Vol. 34, No. 4, 2014, pp. 677-702.
[145] Wei, Y, and Guo, M. “Zinc-binding sites on selected flavonoids.” Biological Trace Element Research Vol. 161,
No. 2, 2014, pp. 223-30.
[146] Sendrayaperumal, V., et al. “Design, synthesis and characterization of zinc-morin, a metal flavonol complex
and evaluation of its antidiabetic potential in HFD-STZ induced type 2 diabetes in rats.” Chemico-Biological
Interactions Vol. 219, 2014, pp. 9-17.
[147] Chausmer, A.B. “Zinc, insulin and diabetes.” Journal of the American College of Nutrition Vol. 17, No. 2, 1998,
pp. 109-15
[148] V., Sendrayaperumal, and Subramanian S. “Zinc-Morin complex augments normoglycemia by regulating the
carbohydrate metabolic enzymes in high fat diet - STZ induced experimental diabetes in rats.” Journal of
Pharmacy Research Vol. 8, No. 11, 2014, pp. 1665-70.
Choudhury, et al. Int J Med Res Health Sci 2017, 6(11): 175-194
191
[149] Zhang, H-X, and Ping M., “Synthesis of morin-zinc(II) complex and its interaction with serum albumin.”
Biological Trace Element Research Vol. 143, No. 2, 2011, pp. 677-87
[150] Asgary, S., et al. “The inhibitory effects of pure flavonoids on in vitro protein glycosylation.’ Journal of Herbal
Pharmacotherapy, vol. 2, no. 2, 2002, pp. 47–55
[151] Xiao, J., et al. “Advances in the biotechnological glycosylation of valuable flavonoids.” Biotechnology Advances
Vol. 32, No. 6, 2014, pp. 1145-56
[152] Sautin, Y.Y., and Richard J. Jo. “Uric acid: The oxidant-antioxidant paradox.” Nucleosides, Nucleotides and
Nucleic Acids Vol. 27, No. 6-7, 2008, pp. 608-19.
[153] Glantzounis, G.K., et al. “Uric acid and oxidative stress.” Current Pharmaceutical Design Vol. 11, 2005, p.
41454151.
[154] Rock, K.L., et al. “Uric acid as a danger signal in gout and its comorbidities.” Nature Reviews Rheumatology
Vol. 9, No. 1, 2013, pp. 13-23.
[155] Cos, P., et al. “Structure-activity relationship and classification of flavonoids as inhibitors of xanthine oxidase
and superoxide scavengers.” Journal of Natural Products Vol. 61, No. 1, 1998, pp. 71-76.
[156] Wang, C.P., et al. “Morin improves urate excretion and kidney function through regulation of renal organic ion
transporters in hyperuricemic mice.” Journal of Pharmacy and Pharmaceutical Sciences Vol. 13, No. 3, 2010,
pp. 411-27.
[157] Mo, S-F., et al. “Hypouricemic action of selected flavonoids in mice: Structure-activity relationships.” Biological
& Pharmaceutical Bulletin Vol. 30, No. 8, 2007, pp. 1551-56.
[158] Santos, R., Fabiane, K., et al. “Effect of flavonoids morin; quercetin and nicotinic acid on lipid metabolism of
rats experimentally fed with triton.” Brazilian Archives of Biology and Technology Vol. 44, No. 3, 2001, pp.
263-67.
[159] Spieker, L.E., et al. “The management of hyperuricemia and gout in patients with heart failure.” European
Journal of Heart Failure Vol. 4, No. 4, 2002, pp. 403-10.
[160] Sinha, K, Ghosh, J. et al. “Morin and its role in chronic diseases.” Advances in Experimental Medicine and
Biology Vol. 928, 2016, pp. 453-71.
[161] Dobrian, A.D., et al. “Development of hypertension in a rat model of diet-induced obesity.” Hypertension Vol.
35, No. 4, 2000, pp. 1009-15.
[162] Kotsis, V., et al. “Mechanisms of obesity-induced hypertension.” Hypertension Research Vol. 33, No. 5, 2010,
pp. 386-93.
[163] Rahbar A, Hajian A. “Dyslipidemia frequency and related factors to blood in children suffering from type 1
diabetes.” Biomedical Research Vol. 28, No. 19, 2017, pp. 8402-05.
[164] Zhang Y, Yuqi, et al. “Serum levels of brain-derived neurotrophic factor and clinical efficacy of mirtazapine in
geriatric patients with major depression.” Biomedical Research Vol. 26, No. 2, 2015, pp. 231-36.
[165] Rotstein, Ori D. “Oxidants and antioxidant therapy.” Critical Care Clinics Vol. 17, No. 1, 2001, pp. 239-47.
[166] Herrera, M.D., et al. “Effects of flavonoids on rat aortic smooth muscle contractility: Structure-activity
relationships.” General Pharmacology Vol. 27, No. 2, 1996, pp. 273-77.
[167] Prahalathan, Pi., Kumar, S., et al. “Morin attenuates blood pressure and oxidative stress in deoxycorticosterone
acetate-salt hypertensive rats: A biochemical and histopathological evaluation.” Metabolism: Clinical and
Experimental Vol. 61, No. 8, 2012, pp. 1087-99.
[168] Kang, D.G., et al. “Effects of morin on blood pressure and metabolic changes in fructose-induced hypertensive
rats.” Biological & Pharmaceutical Bulletin Vol. 27, No. 11, 2004, pp. 1779-83.
[169] Taguchi, K., et al. “Effect of short-term polyphenol treatment on endothelial dysfunction and thromboxane A2
levels in streptozotocin-induced diabetic mice.” Biological and Pharmaceutical Bulletin Vol. 37, No. 6, 2014,
pp. 1056-61.
[170] Zhong, Lili, et al. “Recent advances of immune checkpoint in breast cancer.” Biomedical Research Vol. 28, No.
16, 2017, pp. 7268-73.
Choudhury, et al. Int J Med Res Health Sci 2017, 6(11): 175-194
192
[171] Heng, H.H.Q., et al. “The evolutionary mechanism of cancer.” Journal of Cellular Biochemistry, vol. 109, no.
6, 2010, pp. 1072-84.
[172] horne, s.d., et al. “evolutionary mechanism unifies the Hallmarks of cancer.” International Journal of Cancer
Vol. 136, No. 9, 2015, pp. 2012-21.
[173] Dawson, M.A., and Tony Kouzarides. “Cancer epigenetics: From mechanism to therapy.” Cell, Vol. 150, No.
1, 2012, pp. 12-27.
[174] Hyun, H.B., et al. “The flavonoid morin from moraceae induces apoptosis by modulation of Bcl-2 family
members and Fas receptor in HCT 116 cells.” International Journal of Oncology Vol. 46, No. 6, 2015, pp.
2670-78.
[175] Lee, J.H., et al. “Morin, a flavonoid from moraceae, inhibits cancer cell adhesion to endothelial cells and EMT
by down-regulating VCAM-1 and N-cadherin.” Asian Pacific Journal of Cancer Prevention Vol. 17, No. 7,
2016, pp. 3071-75.
[176] Nandhakumar, R., et al. “Morin augments anticarcinogenic and antiproliferative efficacy against
7,12-dimethylbenz(a)-anthracene induced experimental mammary carcinogenesis.” Molecular and Cellular
Biochemistry Vol. 364, No. 1-2, 2012, pp. 79-92.
[177] Hsiang, C-Y, et al. “Morin inhibits 12-O-tetradecanoylphorbol-13-acetate-induced hepatocellular transformation
via activator protein 1 signaling pathway and cell cycle progression.” Biochemical Pharmacology Vol. 69, No.
11, 2005, pp. 1603-11.
[178] Sithara, Thomas, et al. “Morin inhibits proliferation of SW480 colorectal cancer cells by inducing apoptosis
mediated by reactive oxygen species formation and uncoupling of Warburg effect.” Frontiers in Pharmacology
Vol. 8, No. 1, 2017, p. 640.
[179] Brown, J., et al. “Enhanced Sensitivity of Human Oral tumours to the flavonol, morin, during cancer progression:
involvement to the akt and stress Kinase Pathways.” Carcinogenesis Vol. 24, No. 2, 2003, pp. 171-77.
[180] Kuo, H.M., et al. “Morin inhibits the growth of human leukemia HL-60 cells via cell cycle arrest and induction
of apoptosis through mitochondria dependent pathway.” Anticancer Research Vol. 27, No. 1A, 2007, pp. 395-
405.
[181] Romero, I., et al. “Polyphenols in red wine inhibit the proliferation and induce apoptosis of LNCaP Cells.” BJU
International Vol. 89, No. 9, 2002, pp. 950-54.
[182] Gupta, S.C., et al. “Morin inhibits STAT3 tyrosine 705 phosphorylation in tumor cells through activation of
protein tyrosine phosphatase SHP1.” Biochemical Pharmacology Vol. 85, No. 7, 2013, pp. 898-912.
[183] Panhwar, Q.K., and Shahabuddin Memon. “Synthesis of Cr(III)-Morin complex: Characterization and
antioxidant study.” The Scientific World Journal Vol. 2014, 2014.
[184] Pieniązek, E.A., et al. “Syntheses, crystal structures and antioxidant study of Zn(II) complexes with morin-5′-
sulfonic acid (MSA).” Journal of Inorganic Biochemistry Vol. 141, 2014, pp. 180-87.
[185] Hodek, P., et al. “Flavonoids-potent and versatile biologically active compounds interacting with cytochromes
P450.” Chemico-Biological Interactions Vol. 139, No. 1, 2002, pp. 1-21.
[186] Singh, M.S., et al. “Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.’ Breast (Edinburgh,
Scotland), vol. 20, no. 2, 2011, pp. 111-18.
[187] Si, D., et al. “Mechanism of CYP2C9 inhibition by flavones and flavonols.” Drug Metabolism and Disposition
Vol. 37, No. 3, 2009, pp. 629-34.
[188] Germann, U.A. “P-glycoprotein - A mediator of multidrug resistance in tumour cells.” European Journal of
Cancer Vol. 32, No. 6, 1996, pp. 927-44.
[189] Suzuki, H., and Sugiyama, Y., “Role of metabolic enzymes and efflux transporters in the absorption of drugs
from the small intestine.” European Journal of Pharmaceutical Sciences Vol. 12, No. 1, 2000, pp. 3-12.
[190] Pathak, S.M., and Udupa N. “Pre-clinical evidence of enhanced oral bioavailability of the P-glycoprotein
substrate talinolol in combination with morin.” Biopharmaceutics and Drug Disposition Vol. 31, No. 2-3, 2010,
Choudhury, et al. Int J Med Res Health Sci 2017, 6(11): 175-194
193
pp. 202-14.
[191] Priya, Ratna, et al. “Oxidative stress in psoriasis.” Biomedical Research, Vol. 25, No. 1, 2013, pp. 132-34.
[192] O’Rourke, Robert W. “Inflammation in obesity-related diseases.” Surgery, Vol. 145, No. 3, 2009, pp. 255-59.
[193] Sies, H., “Biochemistry of oxidative stress.” Angewandte Chemie International Edition in English Vol. 25, No.
12, 1986, pp. 1058-71.
[194] Emerit, J., et al. “Neurodegenerative diseases and oxidative stress.” Biomedicine and Pharmacotherapy Vol.
58, No. 1, 2004, pp. 39-46.
[195] Bauer, M.E., and De la M.F. “Oxidative stress, inflammaging, and immunosenescence.” Inflammation,
Advancing Age and Nutrition: Research and Clinical Interventions 2013, pp. 39-47.
[196] Kim, Y.J., et al. “Oxidative stress in inflammation-based gastrointestinal tract diseases: Challenges and
opportunities.” Journal of Gastroenterology and Hepatology, Vol. 27, no. 6, 2012, pp. 1004-10.
[197] Valko, M., et al. “Free radicals and antioxidants in normal physiological functions and human disease.” The
International Journal of Biochemistry & Cell Biology, Vol. 39, No. 39, 2007, pp. 44-84.
[198] Kim, H-S, et al. “New insights into the mechanisms of polyphenols beyond antioxidant properties; Lessons
from the green tea polyphenol, epigallocatechin 3-gallate.” Redox Biology Vol. 2, No. 1, 2014, pp. 187-95.
[199] Park, Ji-Y., et al. “Morin induces heme oxygenase-1 via ERK-Nrf2 signaling pathway.” Journal of Cancer
Prevention Vol. 18, No. 3, 2013, pp. 249-56.
[200] Chang, Mei-Yin, et al. “Evaluation and analysis of phytochemical antioxidant capacity.” Biomedical Research
Vol. 28, No. 14, 2017, pp. 6431-34.
[201] Wolfe, K.L., and Liu, R.H. “Structure-activity relationships of flavonoids in the cellular antioxidant activity
assay.” Journal of Agricultural and Food Chemistry Vol. 56, No. 18, 2008, pp. 8404-11.
[202] Farkas, O., et al. “Quantitative structure-antioxidant activity relationships of flavonoid compounds.” Molecules
(Basel, Switzerland) Vol. 9, No. 12, 2004, pp. 1079-88.
[203] Mendoza-Wilson, A.M., et al. “Spectroscopic and Computational Study of the Major Oxidation Products
Formed during the Reaction of Two Quercetin Conformers with a Free Radical.” Spectrochimica Acta - Part A:
Molecular and Biomolecular Spectroscopy Vol. 81, No. 1, 2011, pp. 481-88.
[204] Morales, J., et al. “Singlet Oxygen Reactions with Flavonoids. A Theoretical-Experimental Study.” PloS One
Vol. 7, No. 7, 2012, p. e40548.
[205] Wu, T.W., Fung, K.P. et al. “Morin Hydrate Inhibits Azo-Initiator Induced Oxidation of Human Low Density
Lipoprotein.” Life Sciences Vol. 58, No. 2, 1995.
[206] Lian, T.W., et al. “Fisetin, Morin and Myricetin Attenuate CD36 Expression and oxLDL Uptake in U937-
Derived Macrophages.” Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids Vol. 1781, No.
10, 2008, pp. 601-09.
[207] Jonnalagadda, Venu Gopal, et al. “Ameliorative Effect of Morin Hydrate, a Flavonoid against Gentamicin
Induced Oxidative Stress and Nephrotoxicity in Sprague-Dawley Rats.” International Journal of Pharmacy and
Pharmaceutical Sciences Vol. 6, No. 1, 2013, pp. 851-56.
[208] Parihar, Vipan Kumar, et al. “Anticlastogenic Activity of Morin against Whole Body Gamma Irradiation in
Swiss Albino Mice.” European Journal of Pharmacology Vol. 557, No. 1, 2007, pp. 58-65.
[209] Zhang, R., Kyoung A-K. and Mei J. P., et al. “Cellular Protection of Morin against the Oxidative Stress Induced
by Hydrogen Peroxide.” Chemico-Biological Interactions, Vol. 177, No. 1, 2009, pp. 21-27.
[210] Merwid-Ląd, A., et al. “The Impact of Morin, a Natural Flavonoid, on Cyclophosphamide-Induced Changes in
the Oxidative Stress Parameters in Rat Livers.” Advances in Clinical and Experimental Medicine Vol. 23, No.
4, 2014, pp. 505-09.
[211] Merwid-Lad, A., et al. “The Effects of Morin, a Naturally Occurring Flavonoid, on Cyclophosphamide-Induced
Toxicity in Rats.” Advances in Clinical and Experimental Medicine Vol. 20, No. 6, 2011, pp. 683-90.
Choudhury, et al. Int J Med Res Health Sci 2017, 6(11): 175-194
194
[212] Kostyuk, V.A., et al. “Influence of Metal Ions on Flavonoid Protection against Asbestos-Induced Cell Injury.”
Archives of Biochemistry and Biophysics Vol. 385, No. 1, 2001, pp. 129-37.
[213] Mira, L., et al. “Interactions of Flavonoids with Iron and Copper Ions: A Mechanism for Their Antioxidant
Activity.” Free Radical Research Vol. 36, No. 11, 2002, pp. 1199-208.
[214] Beker, B.Y., et al. “Protection of Ascorbic Acid from copper(II)-Catalyzed Oxidative Degradation in the
Presence of Flavonoids: Quercetin, Catechin and Morin.” International Journal of Food Sciences and Nutrition
Vol. 62, No. 5, 2011, pp. 504-12.
[215] Zeng L.H., et al. “Morin Hydrate: A Better Protector than Purpurogallin of Corneal Endothelial Cell Damage
Induced by Xanthine Oxidase and SIN-1.” Current Eye Research, Vol. 17, No. 2, 1998, pp. 149-52.
[216] Sivaramakrishnan, V., et al. “Attenuation of N-Nitrosodiethylamine-Induced Hepatocellular Carcinogenesis by
a Novel Flavonol-Morin.” Chemico-Biological Interactions, Vol. 171, No. 1, 2008, pp. 79-88.
[217] Han CL, Fu R., and Lei W.F. “Synthesis and Antidementia Effects of a New Zn (II) Coordination Polymer.”
Biomedical Research Vol. 27, No. 4, 2016, pp. 1237-39.
[218] Mora, Martha, L. “The Application of DTI to Investigate Abnormalities in Schizophrenia and Alzheimer
Disease.” Biomedical Research Vol. 26, No. 4, 2015, pp. 621-24.
[219] Passos, Clévia Santos, et al. “Obesity, Inflammation, Physical Inactivity and Risk for Cancer.” Journal of
Medical Oncology and Therapeutics Vol. 2, No. 1, 2017, pp. 16-19.
[220] Libby, P., et al. “Inflammation and Atherosclerosis.” Circulation, Vol. 105, No. 9, 2002, pp. 1135-43.
[221] Shoelson, S.E., et al. “Obesity, Inflammation, and Insulin Resistance.” Gastroenterology, Vol. 132, No. 6, 2007,
pp. 2169-80.
[222] Sinha, K. and Sadhukhan, P., et al. “Morin Protects Gastric Mucosa from Nonsteroidal Anti-Inflammatory Drug,
Indomethacin Induced Inflammatory Damage and Apoptosis by Modulating NF-kB Pathway.” Biochimica et
Biophysica Acta - General Subjects Vol. 1850, No. 4, 2015, pp. 769-83.
[223] Ma, Y., et al. “Morin Attenuates Ovalbumin-Induced Airway Inflammation by Modulating Oxidative Stress-
Responsive MAPK Signaling.” Oxidative Medicine and Cellular Longevity Vol. 2016, 2016.
[224] Wallace, J.L., et al. “Hapten-Induced Chronic Colitis in the Rat: Alternatives to Trinitrobenzene Sulfonic Acid.”
Journal of Pharmacological and Toxicological Methods, Vol. 33, No. 4, 1995, pp. 237-39.
[225] Kim, H-K., et al. “Effects of Naturally Occurring Flavonoids on Nitric Oxide Production in the Macrophage
Cell Line RAW 264.7 and Their Structure-Activity Relationships.” Biochemical Pharmacology Vol. 58, No. 5,
1999, pp. 759-65.
[226] Alvarez, S.E., et al. “Sphingosine-1-Phosphate Is a Missing Cofactor for the E3 Ubiquitin Ligase TRAF2.”
Nature Vol. 465, No. 7301, 2010, pp. 1084-88,
[227] Cowart, L.A. “Sphingolipids: Players in the Pathology of Metabolic Disease.” Trends in Endocrinology and
Metabolism Vol. 20, No. 1, 2009, pp. 34-42.
[228] Lee, H.S., et al. “Morin Protects Acute Liver Damage by Carbon Tetrachloride (CCl4) in Rat.” Archives of
Pharmacal Research Vol. 31, No. 9, 2008, pp. 1160-65.